K
Karen M. Grimm
Researcher at United States Military Academy
Publications - 11
Citations - 1889
Karen M. Grimm is an academic researcher from United States Military Academy. The author has contributed to research in topics: Antigen & CD8. The author has an hindex of 8, co-authored 11 publications receiving 1863 citations. Previous affiliations of Karen M. Grimm include Merck & Co..
Papers
More filters
Journal ArticleDOI
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
John W. Shiver,Tong-Ming Fu,Ling Chen,Danilo R. Casimiro,Mary-Ellen Davies,Robert K. Evans,Zhiqiang Zhang,Adam J. Simon,Wendy L. Trigona,Sheri Dubey,Lingyi Huang,Virginia Harris,Romnie Long,Xiaoping Liang,Larry Handt,William A. Schleif,Lan Zhu,Daniel C. Freed,Natasha Persaud,Liming Guan,Kara Punt,Aimin Tang,Minchun Chen,Keith A. Wilson,Kelly B. Collins,Gwendolyn J. Heidecker,V. Rose Fernandez,Helen C. Perry,Joseph G. Joyce,Karen M. Grimm,James C. Cook,Paul M. Keller,Denise S. Kresock,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,Zheng Xu,Kathryn E. Bohannon,David B. Volkin,David C. Montefiori,Ayako Miura,Georgia R. Krivulka,Michelle A. Lifton,Marcelo J. Kuroda,Jörn E. Schmitz,Norman L. Letvin,Michael J. Caulfield,Andrew J. Bett,Rima Youil,David C. Kaslow,Emilio A. Emini +51 more
TL;DR: The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector.
Journal ArticleDOI
Solution State Characterization of Amyloid β-Derived Diffusible Ligands
Robert W. Hepler,Karen M. Grimm,Deborah D. Nahas,Robert Breese,Elizabeth Chen Dodson,Paul Acton,Paul M. Keller,Mark Yeager,Hui Wang,Paul J. Shughrue,Gene G. Kinney,Joseph G. Joyce +11 more
TL;DR: This work has studied the solution behavior of various amyloid peptide preparations using analytical ultracentrifugation and size exclusion chromatography coupled with multiangle laser light scattering to indicate that ADDL preparations exist in solution primarily as a binary mixture of a monomeric peptide and high-molecular mass oligom...
Journal ArticleDOI
An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions
Joseph G. Joyce,Isaac J. Krauss,Hong C. Song,David Opalka,Karen M. Grimm,Deborah D. Nahas,Mark T. Esser,Renee Hrin,Meizhen Feng,Vadim Y. Dudkin,Michael Chastain,John W. Shiver,Samuel J. Danishefsky +12 more
TL;DR: Evidence is presented from both direct and competitive binding assays that no significant recognition of the glycopeptides was observed, although certain sera did contain antibodies that could compete with 2G12 for binding to recombinant gp120.
Journal ArticleDOI
Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureus.
Joseph G. Joyce,Chitrananda Abeygunawardana,Qiuwei Xu,James C. Cook,Robert W. Hepler,Craig T. Przysiecki,Karen M. Grimm,Keith Roper,Charlotte C Ip,Leslie Cope,Donna L. Montgomery,Mason Chang,Sherilyn Campie,Martha Brown,Tessie McNeely,Julie Zorman,Tomas Maira-Litran,Gerald B. Pier,Paul M. Keller,Kathrin U. Jansen,George E. Mark +20 more
TL;DR: It is demonstrated that MN8m produced a high-molecular-weight polymer of beta-(1-->6)-linked glucosamine containing 45-60% N-acetyl, and a small amount of O-succinyl (approx 10% mole ratio to monosaccharide units) that is chemically and biologically closely related to the PIA produced by S. aureus.
Journal ArticleDOI
Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys
Tong-Ming Fu,Karen M. Grimm,Michael P. Citron,Daniel C. Freed,Jiang Fan,Paul M. Keller,John W. Shiver,Xiaoping Liang,Joseph G. Joyce +8 more
TL;DR: Surprisingly, HBVc expressing M2 peptide was an inferior vaccine in rhesus monkeys, whether as a primary vaccine or as a booster vaccine, when compared with M2-OMPC conjugate vaccine.